Connect your AI

ImmunityBio, Inc. IBRX Issuance of common stock for the acquisition of Ansys

Issuance of common stock for the acquisition of Ansys at other companies

Apogee Therapeutics, Inc.APGE

——

Other financials

Income statement

Revenue$44.2M+168%

Gross profit$44.0M+167%

Operating income-$69.8M-8.3%

Net income-$632.8M-388%

EPS (diluted)-$0.62-313%

Balance sheet

Cash & equivalents$205.2M+238%

Total debt$445.4M+32.2%

Total equity-$870.0M-47.1%

Total assets$646.6M+113%

Cash flow

Operating cash flow-$75.4M+12.3%

CapEx$1.8M+58.4%

Free cash flow-$77.1M+11.4%

Valuation

Market cap$7.71B+208%

Enterprise value$7.95B+187%

P/S54.7×-25.4×

Profitability

Gross margin99.3%-0.5pp

Operating margin-185.4%-83.3pp

Net margin-606.2%-212pp

FCF margin-212%-95.8pp

Returns & leverage

Return on equity-119.3%—

Debt / equity0.1×—

Current ratio6.7×+4.4×

Where this comes from

Reported directly by ImmunityBio, Inc. in its filing.

Tagged under the XBRL concept us-gaap:StockIssued1.

The official record: ImmunityBio, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about ImmunityBio, Inc.'s issuance of common stock for the acquisition of ansys.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is ImmunityBio, Inc.'s issuance of common stock for the acquisition of ansys?: ImmunityBio, Inc. (IBRX) reported issuance of common stock for the acquisition of ansys of $16.38M in Q1 2026.
How has ImmunityBio, Inc.'s issuance of common stock for the acquisition of ansys changed year-over-year?: ImmunityBio, Inc.'s issuance of common stock for the acquisition of ansys increased by 446.9% year-over-year, from $3M to $16.38M.